Singapore startup Leben Care raises funding to provide AI-based retinal diagnostics solutions
Singapore-based Leben Care Technologies, which provides AI-powered retinal diagnostics and screening solutions, has secured an undisclosed amount in funding from India-based IP Ventures.
The startup will use the funds to strengthen its product, sales and marketing teams.
Leben Care is focused on improving quality of diagnosis across the areas of life sciences. Its flagship Netra.AI enables automated and point of care retinal image analysis by reducing incidence of blindness by timely identification of patients at risk and offering insights to medical practitioners, thus enabling improved diagnostic outcome.
Leben Care enables automated analysis of retina image using AI algorithms that can be used by technicians, nurses, optometrists to conduct basic screening with minimal specialist intervention, delivering real-time reports. The company will also cater to areas such as Glaucoma and age-related macular edema.
The company has businesses in India, Japan, China, Africa and Australia, besides Singapore, through partnerships with distributors & ophthalmology centers across these countries.
Leben Care Co-founder Nitin Srivastava said: “We are on a mission to fight avoidable blindness using AI and hope to make this technology available to millions who struggle to get access to basic screening. Our platform Netra.ai is intended to be the go to place for all Ophthalmology related AI solutions.”
Mitesh Shah, Co-founder of IP Ventures, said: “In our country and even worldwide, there is a huge supply deficit when it comes to screening and diagnostic ophthalmology services. Leben Care is using AI and scalable technology to address this problem.”